Allos Therapeutics to Report First Quarter 2010 Financial Results on May 5, 2010

WESTMINSTER, Colo.--(BUSINESS WIRE)-- Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics, today announced that Company management will provide a corporate update and review of the first quarter 2010 financial results via webcast and conference call on Wednesday, May 5, 2010, at 4:30 p.m. ET.

To access the live audio webcast or the subsequent archived recording, visit the “Investors - Presentations and Events” section of the Company’s website at Alternatively, callers may participate in the conference call by dialing 1-877-941-0844 (domestic) or 480-629-9644 (international). Participants should reference the Allos Therapeutics conference call. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through May 19, 2010. To access the replay, callers should dial 1-800-406-7325 (domestic) or 303-590-3030 (international) and use passcode 4285655#.

About Allos Therapeutics

Allos Therapeutics, Inc. (Nasdaq:ALTH) is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. Allos is currently focused on the development and commercialization of FOLOTYN® (pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Allos is also developing FOLOTYN in other potential indications. Allos retains exclusive worldwide rights to FOLOTYN for all indications. Allos is headquartered in Westminster, Colo. For additional information, please visit

Safe Harbor Statement

The first quarter 2010 financial results press release and conference call will contain forward-looking statements that involve significant risks and uncertainties, including those contained in the "Risk Factors" section of the Company's Form 10-K for the year ended December 31, 2009 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. Allos is providing the information contained in the press release and conference call as of the date of the release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the press release or the conference call. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected.


Allos Therapeutics, Inc.
Monique Greer, 720-540-5268
[email protected]

KEYWORDS:   United States  North America  Colorado

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Radiology  General Health



Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.